Atrial fibrillation, bleeding, infection, and other adverse events may occur with this therapy.
Shan Li O'Connor, PharmD, BCOP
Advertisement
Articles by Shan Li O'Connor, PharmD, BCOP
Advertisement
Latest Updated Articles
Management of Bruton Tyrosine Kinase Inhibitor–Associated ToxicitiesPublished: August 17th 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Interview with Sa'ed al-Olimat, PharmD: How Pharmacists are Shaping the Future of Psychedelic Therapy
2
December 2025 Product Updates
3
A Healthy Gut Could Improve Mental Health
4
Reimagining Pharmacy: A Call to Action for Pharmacy Professionals
5